* Royalty submits offer document for Elan Corp
* Says only prepared to offer fair price for Tysabri
* Elan has already rejected bid, teeing up other deals
* Royalty says share buyback was attempt to frustrate bid
* Elan shares down 1.6 pct in Dublin
DUBLIN, May 2 Royalty Pharma
submitted its $11.25 per share bid for Elan to
the Irish drugmaker's shareholders on Thursday, standing by its
reduced price in the face of the target's insistence it is worth
Elan had rejected Royalty's bid last month in a takeover
saga that has entered its third month and is instead teeing up a
number of deals to reshape the company and help stave off the
U.S. investment firm's interest.
Royalty made its initial approach in February, attracted by
the promise of lucrative revenues from Elan's multiple sclerosis
drug Tysabri. But Elan has fought to maintain its independence
through a series of manoeuvres designed to frustrate the bid,
which is contingent on 90 percent acceptances.
Elan sold its 50 percent interest in the blockbuster MS drug
to U.S. partner Biogen Idec for $3.25 billion plus
royalty rights of up to 25 percent. It will hand over a fifth of
that royalty stream to shareholders.
Royalty said on Thursday it believed its offer put an
implied value of $3.9 billion on Tysabri, a price shareholders
should welcome, but added it was not prepared to pay over the
odds to add the drug to its stable of royalty streams.
"Royalty Pharma takes note of recent multiple sclerosis
market trends, specifically slowing net patient additions for
Tysabri reported by Biogen for Q1 (2013) ... and the strong
initial launch of (MS pill) Tecfidera," Royalty Chief Executive
Pablo Legorreta said in a statement.
"Although Royalty Pharma continues to be interested in
acquiring Elan, Royalty Pharma is a disciplined financial buyer
and is only prepared to offer a price for Elan that reflects the
fundamental value of the Tysabri royalty."
Royalty last month lowered its bid to $11.25 a share from an
earlier $12, pricing in the result of a $1 billion share buyback
Legorreta said the buyback was an attempt to frustrate
Royalty's offer and warned shareholders that the alternative
they face was to accept the risks of Elan management's
Some analysts have questioned Elan's lack of experience in
pulling off major deals, while others believe Royalty needs to
come back with improved terms to temp shareholders.
Shares in Elan, which closed at $11.60 in New York on
Monday, fell 1.6 percent to 8.6 euros ($11.35) at 1200 GMT in
Dublin, where the company keeps a secondary listing.
($1 = 0.7580 euros)
(Reporting by Padraic Halpin; Editing by David Holmes)